281 related articles for article (PubMed ID: 19024280)
1. [Rituximab (Mabthera)--treatment of rheumatoid arthritis patients with inadequate response to TNF inhibitors--when to change therapy?].
Morović-Vergles J
Reumatizam; 2008; 55(2):70-2. PubMed ID: 19024280
[TBL] [Abstract][Full Text] [Related]
2. [B cell depletion therapy using anti-CD20 antibodies in rheumatoid arthritis].
Yukawa N; Mimori T
Clin Calcium; 2007 Apr; 17(4):569-76. PubMed ID: 17404487
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis.
Korhonen R; Moilanen E
Basic Clin Pharmacol Toxicol; 2010 Jan; 106(1):13-21. PubMed ID: 19686542
[TBL] [Abstract][Full Text] [Related]
4. Long term treatment of rheumatoid arthritis with rituximab.
Caporali R; Caprioli M; Bobbio-Pallavicini F; Bugatti S; Montecucco C
Autoimmun Rev; 2009 Jun; 8(7):591-4. PubMed ID: 19393205
[TBL] [Abstract][Full Text] [Related]
5. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience.
Jois RN; Masding A; Somerville M; Gaffney K; Scott DG
Rheumatology (Oxford); 2007 Jun; 46(6):980-2. PubMed ID: 17384180
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy.
Bokarewa M; Lindholm C; Zendjanchi K; Nadali M; Tarkowski A
Scand J Immunol; 2007 Oct; 66(4):476-83. PubMed ID: 17850593
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for the treatment of rheumatoid arthritis.
Schuna AA
Pharmacotherapy; 2007 Dec; 27(12):1702-10. PubMed ID: 18041890
[TBL] [Abstract][Full Text] [Related]
8. Emerging biologic drugs for the treatment of rheumatoid arthritis.
Puppo F; Murdaca G; Ghio M; Indiveri F
Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
[TBL] [Abstract][Full Text] [Related]
9. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.
Salliot C; Finckh A; Katchamart W; Lu Y; Sun Y; Bombardier C; Keystone E
Ann Rheum Dis; 2011 Feb; 70(2):266-71. PubMed ID: 21097801
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
Isaacs JD
Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731
[TBL] [Abstract][Full Text] [Related]
11. [Rituximab (MabThera)--a new biological medicine in rheumatoid arthritis therapy].
Nemec P
Vnitr Lek; 2007 Nov; 53(11):1199-210. PubMed ID: 18277630
[TBL] [Abstract][Full Text] [Related]
12. B cell depletion in early rheumatoid arthritis: a new concept in therapeutics.
Renato GM
Ann N Y Acad Sci; 2009 Sep; 1173():729-35. PubMed ID: 19758222
[TBL] [Abstract][Full Text] [Related]
13. [Targeting CD20 in rheumatoid arthritis].
Saito K; Tanaka Y
Nihon Rinsho; 2007 Jul; 65(7):1243-9. PubMed ID: 17642239
[TBL] [Abstract][Full Text] [Related]
14. Switching rheumatoid arthritis treatments: an update.
Atzeni F; Sarzi-Puttini P; Gorla R; Marchesoni A; Caporali R
Autoimmun Rev; 2011 May; 10(7):397-403. PubMed ID: 21262393
[TBL] [Abstract][Full Text] [Related]
15. Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
Belmonte Serrano MA; Pincus T
Rheumatology (Oxford); 2010 Sep; 49(9):1795-6; author reply 1796-7. PubMed ID: 20484342
[No Abstract] [Full Text] [Related]
16. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application.
Mease PJ
J Rheumatol; 2008 Jul; 35(7):1245-55. PubMed ID: 18609733
[TBL] [Abstract][Full Text] [Related]
17. Rituximab therapy in rheumatoid arthritis in daily practice.
Assous N; Gossec L; Dieudé P; Meyer O; Dougados M; Kahan A; Allanore Y
J Rheumatol; 2008 Jan; 35(1):31-4. PubMed ID: 18176989
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
[TBL] [Abstract][Full Text] [Related]
19. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy.
Gonzalez-Juanatey C; Llorca J; Vazquez-Rodriguez TR; Diaz-Varela N; Garcia-Quiroga H; Gonzalez-Gay MA
Arthritis Rheum; 2008 Dec; 59(12):1821-4. PubMed ID: 19035415
[TBL] [Abstract][Full Text] [Related]
20. [Rituximab (MabThera) as treatment of active rheumatoid arthritis].
El Fassi D; Nielsen CH; Bendtzen K
Ugeskr Laeger; 2006 Nov; 168(47):4079-81. PubMed ID: 17134602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
